Comparative Pharmacology
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus SPECTRACEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus SPECTRACEF.
CEPHAPIRIN SODIUM vs SPECTRACEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
Cefditoren, a third-generation cephalosporin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
500 mg to 1 g IM or IV every 6 hours.
400 mg orally twice daily for 10-14 days.
None Documented
None Documented
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 2.5 hours (range 2.0-3.0 hours) in healthy adults; prolonged in renal impairment (up to 10 hours in severe impairment)
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 88% as unchanged drug, Fecal: negligible, Biliary: minimal
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic